Clinical Trial Update: RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial of RO4929097 in children with relapsed/refractory solid or CNS tumors, lymphoma, or T-cell leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Lymphoma
• Osteosarcoma
• Sarcoma
• T-cell Leukemia
• Wilms Tumor

Drugs mentioned

• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma, Brain Neoplasms | Phase 1 | Status: WITHDRAWN